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Abstract
We have performed the first extensive profiling of Epstein-Barr virus (EBV) miRNAs on in vivo derived normal and neoplastic
infected tissues. We describe a unique pattern of viral miRNA expression by normal infected cells in vivo expressing
restricted viral latency programs (germinal center: Latency II and memory B: Latency I/0). This includes the complete
absence of 15 of the 34 miRNAs profiled. These consist of 12 BART miRNAs (including approximately half of Cluster 2) and 3
of the 4 BHRF1 miRNAs. All but 2 of these absent miRNAs become expressed during EBV driven growth (Latency III).
Furthermore, EBV driven growth is accompanied by a 5–10 fold down regulation in the level of the BART miRNAs expressed
in germinal center and memory B cells. Therefore, Latency III also expresses a unique pattern of viral miRNAs. We refer to the
miRNAs that are specifically expressed in EBV driven growth as the Latency III associated miRNAs. In EBV associated tumors
that employ Latency I or II (Burkitt’s lymphoma, Hodgkin’s disease, nasopharyngeal carcinoma and gastric carcinoma), the
Latency III associated BART but not BHRF1 miRNAs are up regulated. Thus BART miRNA expression is deregulated in the EBV
associated tumors. This is the first demonstration that Latency III specific genes (the Latency III associated BARTs) can be
expressed in these tumors. The EBV associated tumors demonstrate very similar patterns of miRNA expression yet were
readily distinguished when the expression data were analyzed either by heat-map/clustering or principal component
analysis. Systematic analysis revealed that the information distinguishing the tumor types was redundant and distributed
across all the miRNAs. This resembles ‘‘secret sharing’’ algorithms where information can be distributed among a large
number of recipients in such a way that any combination of a small number of recipients is able to understand the message.
Biologically, this may be a consequence of functional redundancy between the miRNAs.
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Introduction
Epstein-Barr virus (EBV), a member of the gamma-herpesvirus
family, is the most common virus in the human population[1]. It
infects nearly 95% of adults and persists latently for the lifetime of
healthy hosts. In the generally accepted model of EBV persistence,
the virus initiates infection by crossing the epithelium of the oro-
pharynx and infecting resting naı¨ve B cells in Waldeyer’s ring
[2,3]. The establishment of persistent infection is characterized by
the sequential employment of a series of latency transcription
programs that allow the virus to drive the newly infected naı¨ve B
cell into the memory B cell compartment. Initially newly infected
cells express all of the nine known latent proteins (Latency III)
whose function is to cause the resting B cell to become an activated
lymphoblast. This program may be important for cancer
development, because it is capable of initiating the activation of
B cells in vitro into continuously proliferating lymphoblastoid cell
lines (LCL). Furthermore, some of the latent proteins have been
shown to possess oncogenic, pro-proliferation and/or pro-survival
functions that could contribute to the development of malignancy
[4]. The activated naı¨ve B lymphoblasts in vivo rapidly migrate to
the follicle to participate in a germinal center reaction [5,6]. Here
they continue to proliferate but, unlike in vitro, they switch to a
more restricted latency program (Latency II) where only three of
the latent proteins are expressed. Ultimately the cells leave the
germinal center as resting memory B cells (MemB) – the site of
long term latent persistent infection. In MemB cells, all viral
protein expression is extinguished (Latency 0) except when the
cells divide and express EBNA1 (Latency 1), the protein required
for replication of the viral genome. This mechanism is thought to
allow EBV infected cells to escape immune surveillance, enabling
lifelong persistence.
EBV was discovered in Burkitt’s lymphoma (BL) and was the
first human tumor virus identified. Subsequent studies revealed
that the virus is associated with several other lymphoid and
epithelial malignancies including Hodgkin’s disease (HD), naso-
pharyngeal (NPC) and gastric carcinomas (GaCa) (reviewed in
[1,7]). Surprisingly, none of the tumors that arise in immunocom-
petent individuals uses the viral growth promoting program
Latency III. Instead they use Latency I (BL) and II (HD, NPC and
GaCa), Latency III specific transcription is not detected. Several
lines of evidence have led to the suggestion that certain stages of
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the EBV life cycle are linked to the pathogenesis of distinct cancer
types expressing the equivalent latency program. Thus EBV-
positive BL cell has been linked with MemB cells and HD with
germinal center B cells (GCB) [7].
Numerous studies have focused on analyzing and interpreting
the function of the viral latent proteins in order to better
understand their contribution to tumorigenesis. Recently, atten-
tion has been directed toward EBV microRNAs (miRNAs) that
are expressed in latently infected cells. miRNAs are short
noncoding RNAs, average length 22 nucleotides, that post
transcriptionally regulate gene expression [8,9]. They function
either by repressing translation or inducing mRNA degradation.
An increasing body of literature suggests that miRNAs are
involved in a wide array of biological events. With studies using
molecular biology, computational analysis and newly emerging
deep sequencing techniques, 44 mature EBV miRNAs derived
from 25 precursors have been described [10–13]. EBV miRNAs
are mainly encoded from two regions: BHRF1 (Bam HI fragment
H rightward open reading frame 1) and BART (Bam HI-A region
rightward transcript) (Figure 1). miRNAs are the only known
functional products of the BART transcripts [14]. BHRF1
derived miRNAs were reported to be highly expressed in LCL
(Latency III) [10,13], whereas BART miRNAs have been found
in all EBV-infected cell lines tested including LCL, BL and NPC
and tumor biopsies from NPC, GaCa and DLBCL [10,11,13,15–
18]. However a comprehensive comparative accounting is lacking
since most studies only examined a limited repertoire of miRNAs
(frequently with non- or semi quantitative techniques), a limited
range of tissues was studied (frequently employing cell lines
instead of fresh infected tissue) and appropriate computational
methods for data mining were not employed. Using quantitative
multiplex RT-PCR with specific 69FAM-probes and primers for
each miRNA, we have reported previously an EBV miRNA
profile for NPC tissues [16] however a comparable profile does
not currently exist for the other EBV associated tumors including
BL, HD and GaCa. Therefore it is unknown if there is tumor
specific variation in the patterns of EBV miRNA expression. A
number of investigations have previously focused on the profiling
of human cellular miRNAs in B-cell subpopulations and B cell
associated lymphomas (for example, see [19–24]). However,
nothing is known about the expression of EBV miRNAs in
normal infected B cells in vivo and consequently it is unknown if
there are specific changes in their expression associated with
tumorigenesis.
Several groups have identified potential functions or targets for
EBV miRNAs. It has been reported that the BHRF1 miRNAs are
associated with Latency III and viral replication [15,25–27],
chemokine modulation [28] and cell cycle progression and
proliferation [26]. There are conflicting reports about the possible
role of the BARTs. They are suggested to regulate both viral [29–
31] and cellular proteins associated with apoptosis, survival and
immune evasion [32–34]. However, they are dispensable for
infection and immortalization of B cells in vitro [35] and their
absence had no reported effect on susceptibility to apoptosis of
infected B cells [26]. This raises the possibility that the BART
miRNAs may have an important role to play during normal
infection of B cells in vivo that is not required in vitro. This
parallels the behavior of LMP2 for example which is believed to
play an important signaling and survival role in vivo as a B cell
receptor surrogate but is completely dispensable for immortaliza-
tion in vitro [36,37].
Therefore there is an immediate need to characterize and
understand the expression profiles of EBV miRNAs in normal
infected B cell populations and tumors in vivo. In the present
study, we aimed to quantitatively assess and computationally
analyze the miRNA expression profiles in EBV-associated tumor
biopsies (NPC, GaCa, BL, HD) and EBV-infected LCL, GCB and
MemB cells from normal populations. The goal was to discover if
subsets of miRNAs are associated with specific latency programs
and if these expression profiles are disrupted during tumor
development. We present the first demonstration of deregulation
of EBV miRNA expression associated with tumorigenesis.
Specifically, we identify a subset of BART miRNAs that are
restricted to Latency III in normal infection but are up regulated
in tumors that express Latency I and II.
Results
EBV miRNA profiling of normal and neoplastic tissues
We have previously described a technique that allows the
profiling of EBV miRNAs in small amounts of EBV positive tissue
[16]. We have now used this technique to profile EBV miRNA
expression in primary infected normal tissues and tumor biopsies.
The tissues tested are listed in Table 1. For the normal tissues, we
profiled latently infected germinal center B cells (GCB, Latency II)
from the tonsils (n = 5) and latently infected memory B cells
(MemB, Latency I/0) from the peripheral blood (n= 4) all derived
from normal, persistently infected individuals. For the tumors, we
profiled four types of primary biopsies including Burkitt’s
lymphoma (BL: n= 6, Latency I), gastric carcinoma (GaCa:
n = 6, Latency II), nasopharyngeal carcinoma (NPC: n= 5,
Latency II) and Hodgkin’s disease (HD: n= 3 Latency II)
(Figure 2). For the tumor biopsies, we could either normalize the
results to the cellular small RNA U6 or by fraction of total viral
miRNAs. However, normalization to U6 was not meaningful for
the GCB and MemB cells because the fraction of infected cells in
these samples was both very low and variable. Therefore to
compare tumor biopsies with normal infected tissue, we expressed
each miRNA as a fraction of total EBV miRNAs. The results for
expression of the BART miRNAs are shown in Figure 3. There
were two striking findings. The first was that despite the disparate
tissue origins of the biopsies and the viral latency programs they
represent, the profiles for all four tumor types were remarkably
similar (Figure 3A). Second, the profiles for the two normal
infected tissues (GCB and MemB) were markedly different from
the tumors but similar to each other (Figure 3B), despite again
Author Summary
miRNAs are small (,22 bp) RNAs. They play central roles in
many cellular processes. Epstein-Barr virus (EBV) is an
important human pathogen that establishes persistent
infection in nearly all humans and is associated with
several common forms of cancer. To achieve persistent
infection, the virus infects B cells and uses a series of
discrete transcription programs to drive these B cells to
become memory B cells – the site of long term persistent
infection. It was the first human virus found to express
miRNAs of which there are at least 40. The functions of a
few of these miRNAs are known but their expression in
latently infected normal and neoplastic tissues in vivo have
not been described. Here we have profiled EBV miRNAs in
a wide range of infected normal and neoplastic tissue. We
demonstrate that there are indeed latency program
specific patterns of viral miRNA expression and that these
patterns are disrupted in EBV associated tumors implicat-
ing EBV miRNAs both in long term persistence and in
oncogenesis.
EBV Latency miRNA Pattern Disrupted in Neoplasia
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originating from different tissues and employing different latency
program. Therefore the similarity of the profiles was determined
by whether or not the tissue of origin was neoplastic not on the
latency program or the tissue of origin. The most striking
difference was the absence of 11 BART miRNAs from the normal
tissues that are highly expressed in the tumors. These included a
large subset of the Cluster 2 BART miRNAs. Of the 18 Cluster 2
miRNAs tested, all were present in the tumor biopsies but only 8/
18 (44%) were found in the GCB and MemB samples. By
comparison, all 10 Cluster 1 BART miRNAs were present in the
tumor biopsies but only 1 was absent from the GCB and MemB
samples.
We conclude that EBV associated tumors expressing Latency I
and II up regulate a subset of BART miRNAs that are silenced in
their normal infected counterparts in vivo.
The Cluster 2 BART miRNAs absent from normal infected
tissues are expressed in Latency III
One possible explanation for the different patterns described
above is that the absent 11 BART miRNAs are associated with
cellular proliferation and become down regulated when the cells
enter a resting state. However, we can exclude this possibility
because infected GCB are proliferating[6]. We therefore investi-
gated an alternate hypothesis namely that these miRNAs are
normally specifically expressed only in Latency III (infected
lymphoblasts) i.e. with virus driven proliferation, and that their
presence in tumors represents aberrant expression. To test this
hypothesis we could apply a more quantitative approach since we
are able to estimate absolute copy numbers per cell of the miRNAs
in all three tissue types namely B cells driven to proliferate by EBV
(spontaneous lymphoblastoid cell lines - LCL) derived from
infected individuals (Latency III), GCB (Latency II) and MemB
(Latency1/0). This was possible for the LCL because they are
homogeneous cell lines. For the GCB and MemB samples we
could estimate miRNA copy number per cell by first measuring
the number of infected cells in the samples to be profiled and then
dividing the total copy number of each miRNA by this value. The
result for the BART miRNAs is shown as a bar graph in Figure 4
and the actual values are tallied in Table 2. The results for GCB
and MemB were again very similar indicating that the profiles
were essentially the same both in terms of relative representation
(Figure 3B) and absolute copy number (Figure 4B and Table 2) for
the BART miRNAs. One notable exception was 17-5p which was
almost undetectable in GCB (average 2 copies/cell) but present at
a copy number almost 2 logs higher in MemB (average 110
copies/cell). Of the 18 Cluster 2 miRNAs profiled 2 were
undetected in all three tissues (LCL, GCB and MemB). The
remaining 16 were all present in LCL. As with the tumors this
included the one Cluster 1 and eight Cluster 2 BART miRNAs
that were absent from GCB and MemB samples. A second feature
to emerge from this comparison is that the BART miRNAs that
were detected in GCB and MemB were present at copy numbers
that averaged 5–10 fold higher than in LCL.
We have investigated whether our failure to detect BART
miRNAs from in vivo samples was due to lack of sensitivity of the
PCR reaction rather than true absence. Of the 12 BART miRNAs
that were not detected in GCB and MemB cells 4 were also either
absent or present at marginal levels (,1 copy /cell) in the LCL.
Therefore the failure to detect these in the GCB and MemB may
not be meaningful. However, the remaining 8 absent miRNAs
Figure 1. Schematic representation of the location and ordering of EBV miRNAs within the EBV genome. EBV miRNAs are derived from
two transcripts: BHRF1 and BART (white bars). Precursor miRNAs are listed in the order of genomic location. The location of latent proteins (EBNAs
and LMPs –grey boxes), other transcripts found in latency states (EBER – red box) and their promoters (black flags) are also shown. The V-snoRNA1[57]
is also indicated at the end of the BART transcript.
doi:10.1371/journal.ppat.1002193.g001
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(highlighted in red in Figure 4) were present in LCL at copy
numbers ranging between 5 and 327, identical to the range in
LCL for the BART miRNAs that were found in GCB and MemB
(range 5–250/LCL cell). Therefore the undetected miRNAs were
not consistently those present at low copy numbers in the LCL.
Furthermore, when BART miRNAs were detected in GCB and
MemB cells they were typically detected at higher levels/cell than
in the LCL suggesting that we are not under representing or under
detecting miRNAs in these samples. We also performed profiles on
samples of 106–107 EBV negative tonsils into which had been
spiked various numbers of LCL cells and on GCB and MemB
samples with low numbers of infected cells. We determined that
we could quantitatively profile most of the miRNAs in samples
that contained $1000 infected cells in a population of 106–107
uninfected cells (data not shown). As the number of infected cells
dropped from 1,000 failure of profiling tended to be associated
with drop out of most or all of the miRNAs rather than selective
gradual disappearance. In particular we did not see preferential
drop out of the miRNAs absent from GCB and MemB. This
suggests we may be approaching a general rather than miRNA
specific threshold for profiling. The exceptions were mirBARTs 9,
12, 16 and 19-3p. The PCR for these miRNAs consistently gave
significant signals due to cross reaction with RNA from the large
number of uninfected cells and were therefore excluded from all
analysis. With the exception of one GC sample (600 infected cells)
all of the GCB and MemB samples assayed in our study contained
.1000 infected cells (Table 1).
We conclude that there is a subset of BART miRNAs that reside
predominantly in Cluster 2 and are specifically expressed only
during Latency III in normal infected B cells. We refer to these as
Latency III associated BARTs. Furthermore there is co-ordinate
regulation of the BART miRNAs where approximately one third
are extinguished and two thirds are up regulated as the cells
traverse out of Latency III into Latency I and II.
Expression level of BART miRNAs in tumors
We have established that there is a subset of Latency III
associated BART miRNAs that are also expressed in tumors,
irrespective of latency type. We wished to investigate therefore
whether the absolute level of expression of BART miRNAs in the
tumors also matched those in the LCL i.e. lower compared to
normal tissue. To gain insight into this we compared levels of
BART miRNA expression in LCL and tumor biopsies after
normalization to the ubiquitous small cellular RNA U6. The
results are summarized in Figure 5.
Overall, the pattern of miRNA expression was similar for all of
the tumors (as already shown in Figure 3A when normalized by
fraction) and for the LCL. The LCL, HD and BL were closely
matched (Figure 5A) both in overall pattern and copy number with
the exception that the LCL lacked mirBART 9* and mirBARTs
15 and 18-3p were present at a level more than tenfold higher in
the LCL. Also HD lacked mirBARTs 2-3p, 18-3p and 20-3p
which were among the group of miRNAs absent from GCB and
MemB. However, when LCL were compared with NPC and
GaCa (Figure 5B) it was apparent that the epithelial tumors had
significantly higher overall expression of the BART miRNAs.
When we estimated the average fold increase of the BART
miRNAs in the tumors relative to LCL, we found BL 1: NPC 13:
HD 0.34: GaCa 8. Note that all of the tumors had some levels of
infiltrating non-tumor cells (Figure 2) that would lower the
estimates of miRNA expression. However, with the exception of
HD, these constituted a small (less than half) fraction of the tumors
and would not significantly affect the estimates. Therefore, the
much lower levels of BART miRNAs in HD can be explained at
least in part from the low abundance of tumor cells in these
biopsies. Overall though it appears that the levels of BART
miRNAs in the B cell tumors are comparable to those in the LCL
but 5–10 fold lower than the epithelial tumors.
We conclude therefore that the BART miRNAs are expressed
in all four tumors and that this represents deregulated expression
of the Latency III associated BARTs. HD might represent an
intermediary state where most but not all of the Latency III
associated BART miRNAs are expressed.
Expression of the BHRF1 miRNAs is not deregulated in
the tumors
Previous studies have demonstrated that the BHRF1 miRNAs
are expressed in Latency III where they are reported to play an anti-
apoptotic role [15,25–27]. This result was confirmed in our profiling
(see Table 2 and Figure 6). All four BHRF1 miRNAs were readily
detected in the LCL with copy numbers per cell ranging from 10–
2000 depending on the miRNA and the cell line tested (Table 2 and
Table 1. Tissues and cell lines used in this study.
Name Comment
Peripheral blood MemB cells (CD27+, CD20+)
MemB1 # of infected cells tested = 3.86103
MemB2 # of infected cells tested = 2.36103
MemB3 # of infected cells tested = 1.36103
MemB4 # of infected cells tested = 3.06103
Tonsil GCB cells (CD10+, CD20+)
GCB1 # of infected cells tested = 6.06102
GCB2 # of infected cells tested = 1.06103
GCB3 # of infected cells tested = 6.56103
GCB4 # of infected cells tested = 4.06103
GCB5 # of infected cells tested = 3.86103
Spontaneous LCL
LCL1 A.M from A. Rickinson
LCL2 Angu from A. Rickinson
LCL3 IM43 from A. Rickinson
LCL4 IM86 from A. Rickinson
LCL5 Salina from A. Rickinson
LCL6 IM82 from A. Rickinson
Tumor Biopsies
HD Hodgkin’s disease
NPC Nasopharngeal carcinoma
GaCa Gastric Carcinoma
BL Burkitt’s lymphoma
Tumor Cell Line
L591 Origin: Hodgkin’s disease
C666-1 Origin: Nasopharngeal carcinoma
AGS-BX1 Origin: Gastric Carcinoma
Jijoye Origin: Burkitt’s lymphoma
Rael ‘‘
BL36 ‘‘
Akata 2A8.1 ‘‘
Raji ‘‘
doi:10.1371/journal.ppat.1002193.t001
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not shown). However, they were all absent from GCB (Latency II)
and only one (BHRF1-1) was found in MemB (Latency0/1).
We have demonstrated above that the Latency III associated
pattern of BART miRNA expression is deregulated in all four
tumor types we have studied. To test if this was also true for the
BHRF1 miRNAs, we profiled their expression in all of our tumor
samples and the result, compared to LCL, is shown in Figure 6.
The BHRF1 miRNAs were not detected at all in GaCa and only
sporadically and at low levels in the other tumor biopsies. Using
the LCL values as a standard it is possible to estimate that, with the
exception of BHRF1-1 in HD which was present in , 5 copies, all
of the rest were present at #1 copy per cells. This means that in
the tumor samples the levels of all of the BHRF1 miRNAs were at
least 10 fold lower in expression than in Latency III (LCL). Thus
BHRF1 expression was not consistently deregulated in the tumors.
EBV miRNA profiles distinguish EBV tumor types
We have described a pattern of deregulated BART miRNA
expression in EBV associated tumors however at the crude level of
our analysis we did not detect tumor type specific miRNA
expression. To investigate this more rigorously we have performed
clustering analysis on our data sets using heat maps and principal
component analysis. Figure 7 shows a heat map with clustering
dendrograms of EBV miRNA expression for all of the normal and
tumor tissue samples we have tested normalized by expressing
each miRNA as a fraction of the total EBV miRNAs. The
ordering of the samples across the heat map coincided exactly with
the three major branches of the miRNA dendrograms which in
turn were associated with a functionally distinct group of samples
namely normal tissue (GCB and MemB), LCL and the tumor
biopsies. This analysis did not distinguish between GCB and
MemB cells and the miRNAs responsible for resolving the
GCB+MemB from the LCL (Table 3) coincided with those
already identified above. This served as validation for the
groupings indicated by the heat map. This was important because
the heat map revealed new information namely that the tumors all
formed a discrete branch on both the sample and miRNA
dendrograms (blue box and Table 3) and that within this group the
tumor samples were ordered by tumor type. This was unexpected
given the similarity of the profiles as shown in Figures 3A and 5.
Figure 2. Histological cross sections of typical tumor biopsies used in this study stained for expression of EBV genes. Note that with
the exception of HD less than half of the cells are non-tumor infiltrating lymphocytes. A. Nasopharyngeal carcinoma stained for the EBV nuclear
antigen EBNA1. B. Hodgkin’s disease stained for EBNA1 Note the sparse appearance of the tumor cells compared to the other tumor types. C. Gastric
carcinoma stained for EBNA1 D. Burkitt’s lymphoma stained for the EBV encoded small RNAs EBER.
doi:10.1371/journal.ppat.1002193.g002
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This result was confirmed when we repeated the analysis on a
second set of biopsies (not shown). This implies that there are
tumor specific patterns of EBV miRNA expression. Curiously
though, inspection of the heat maps, failed to identify specific
subsets of miRNAs that could account for this resolution. In an
attempt to understand the basis for this and possibly identify tumor
specific patterns of miRNAs, we analyzed the data by principal
component analysis (PCA). Figures 8 and S2 and Video S1 show
the result from the same data set used for the heat map in Figure 7.
Output for the first three principal components, which account for
55% of all the variation within the normalized data, is shown and
confirms that the different tissue types do indeed cluster discreetly.
When we examined the contributions of different miRNAs to the
first 3 principal components we reproduced the findings from the
heat map (Table 3, Figure S2 ). Of greatest interest was the third
principal component which resolved all four tumor types.
Resolution of the four tumor types could be shown even more
clearly when PCA was performed on the data from the biopsies
alone (Figure 9A and Video S2)and this result was confirmed when
we analyzed data from a second completely independent set of
biopsies (not shown). We performed two tests of the statistical
significance of these results (see Materials and Methods). Both of
these tests showed that successfully separating the four cancer
types has a p-value of approximately 0.001.
We developed a number of analytical tools to try and extract
information about the miRNAs responsible for this effect to no
avail. The reason for this became apparent when we attempted to
identify which miRNAs were essential and which dispensable for
resolving the four tumor types by PCA. To do this we randomly
generated subsets of miRNAs and asked if they were capable of
resolving all four tumor types by PCA. The surprising result,
shown in Figure 9B, was that 10% of such subsets that contained
just 3 miRNAs and 60% that contained 5 miRNAs could resolve
the tumors. When we then looked at which miRNAs were present
in these subsets we found that all of the miRNAs were represented
– there was no subset of miRNAs that was uniquely responsible for
distinguishing the tumors. Similarly when we asked the question:
which miRNAs were dispensable in a given sub-set, i.e. could be
removed without affecting resolution of the tumors, we again
found that all miRNAs were essential in certain subsets (not
shown). This means that the information about the EBV miRNAs
which varies between the tumor types and allows their resolution is
contained in part by all of the miRNAs such that when combined
multiple different subsets of miRNAs contain sufficient informa-
Figure 3. Profile of EBV BART miRNAs in normal and neoplastic tissue. The data is expressed as average and standard deviation of the
fraction that each miRNA constitutes of the total of all EBV miRNAs. A. The four tumor types tested. Blue – Hodgkin’s disease (n = 3): yellow – Burkitt’s
lymphoma (n= 6): green - gastric carcinoma (n = 6): red - nasopharyngeal carcinoma (n = 6). B. Normal infected tissue. Grey – GCB (n = 5), black –
MemB (n= 4). The y intercept is a conservative approximation to the sensitivity of the assay (this will vary according to the input number of infected
cells). It represents the fraction for a miRNA present at 10 copies, the lower limit of sensitivity for detection of all the miRNAs [16]. N.B. The miRNAs are
presented on the x-axis from left to right in the order that they appear in the viral genome (see Figure 1).
doi:10.1371/journal.ppat.1002193.g003
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tion to distinguish the tumors. This phenomenon is reminiscent of
a behavior that is well known in computer science referred to a
‘‘secret sharing’’ [38,39] and represents perhaps a novel and first
description of a biological system where information is so
distributed across a population.
EBV miRNA expression profiles in tumor cell lines are not
representative of the tumors
We have profiled EBV miRNAs from a number of tumor
derived cells lines including 5 BL derived lines and one each of
gastric, nasopharyngeal and Hodgkin’s origin. When this data was
analyzed in a heat map with the data from Figure 7, all of the cell
lines clustered with the LCL not with the tumor biopsies they
originated from (Figure S1). This was most striking for the BL lines
when analyzed by PCA. As shown in Figure 10 and Video S3 the
cluster of BL lines completely intersects the cluster of LCL whereas
the non BL lines lie just outside. The tendency of the tumor cell
lines to drift towards an LCL phenotype was further confirmed
when we analyzed expression of the BHRF1 miRNAs ([16] and
Table 4). As discussed above these miRNAs are associated with
Latency III, the LCL phenotype, and only one is expressed at a
significant level in normal infected tissue or tumor biopsies using
Latency II or I. As shown in the Table they were all expressed at
significant levels in the tumor derived cell lines tested with the
exception of the NPC derived C666-1 cells. We conclude therefore
that miRNA expression in the cell lines is not fully representative
of their tumors of origin.
Discussion
In this paper we have reported on the expression profiling of
EBV miRNAs in a wide variety of infected normal and neoplastic
tissues that express all of the known EBV associated latency
transcription programs. We have shown that there are distinct
patterns of miRNA expression associated with Latency III and the
restricted forms of latency (Latency II/I/0) and that these patterns
are deregulated in EBV associated tumors. GCB (Latency II) and
Figure 4. Profile of EBV BART miRNAs in vivo and in spontaneous lymphoblastoid cell lines (LCL) expressing latency III. The data is
expressed as copy number of each miRNA per infected cell. A. Spontaneous lymphoblastoid cell lines LCL (n = 6). miRNAs that are significantly
expressed in LCL but not GCB and MemB are highlighted in red. B. Normal infected tissue. Grey – GCB (n = 5), black – MemB (n= 4). This is the same
data set as Figure 3A except now expressed as copy number /cell instead of fraction. The y intercept is an approximation to the sensitivity of
detection based on the following. The maximum number of infected cells tested for GCB and MemB was 4–66103 (Table 1). Approximately 0.1% of
the RNA from these samples was used for each PCR reaction i.e. equivalent to ,5 infected cells. Since we can detect as few as 10 copies of each
miRNA [16], we conclude that failure to detect a miRNA in any sample indicates it is present at a copy number#1/cell. The red arrow indicates miRNA
17-5p which was the only miRNA to show a striking differential expression between GCB and MemB cells. N.B. The miRNAs are presented on the x-
axis from left to right in the order that they appear in the viral genome (see Figure 1).
doi:10.1371/journal.ppat.1002193.g004
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MemB (Latency I/0) express the same unique, restricted pattern of
miRNAs with the exception that mirBART 17-5p is preferentially
expressed in MemB cells. This unique pattern includes the absence
of 12 BART miRNAs that include approximately half of Cluster 2.
At least 8 of these absent miRNAs are expressed in B cells
expressing Latency III (LCL) and in all of the tumor biopsies we
have tested although none of the tumors uses Latency III. Thus
this is a Latency III restricted pattern of miRNA expression, which
we refer to as Latency III associated BARTs, that is deregulated in
tumors. Interestingly another group of miRNAs that are associated
with Latency III, the BHRF1s [15,25–27], are not deregulated in
the tumors suggesting that viral miRNA deregulation in the
tumors is specifically targeted at the BARTs. This is an important
conclusion since it represents the first demonstration of Latency III
specific gene expression in tumors that are otherwise expressing
restricted (Latency I/II) forms of latency[1,7] and raises the
possibility that BART miRNAs may contribute to oncogenesis.
The observation of latency program specific miRNA expression
could only have been made by studying in vivo derived infected
material since the Latency III associated BARTs are expressed in
all tumor biopsies and cell lines we have tested.
In the generally accepted model of EBV persistence, newly
infected naı¨ve B lymphoblasts (LCL) expressing Latency III, switch
to Latency II when transiting the germinal center (GCB) to
become resting memory B (MemB) cells, the site of long term
persistence where viral latent protein expression is extinguished
[2,3,7]. Our results here suggest that the transit from EBV driven
growth into more restricted forms of latency in GCB and MemB
cells is associated with turning off expression of the Latency III
associated BARTs and up regulation of the remaining BART
miRNAs by 5–10 fold. This is not simply related to the cessation of
proliferation because latently infected GCB are, like LCL cells,
proliferating [6]. Since proliferation in the GC is not driven by
Latency III, the viral growth program, we may conclude that the
Latency III BART profile (presence of the Latency III associated
BARTs and reduced expression of the remaining BARTs) is
specifically associated with EBV driven growth. One caveat to this
conclusion is that it would have been desirable to confirm the
Latency III pattern of miRNA expression on in vivo infected cells
rather than spontaneous LCL. Unfortunately newly infected tonsil
naı¨ve B cells in vivo are present at a level 5–10 fold lower than
infected GCB [40]. This puts them below the threshold of
sensitivity and reliability for our profiling and therefore was
technically not feasible.
Several studies have reported on potential roles for EBV
miRNAs. There is no striking correlation between these reports
and the BART miRNAs we have as the Latency III associated
BARTs. Marquitz et al [41] have suggested that Cluster 1 and 2
BART miRNAs interact in apoptosis resistance by targeting BIM.
However, their observations are not consistent with those of Seto
et al, who have reported that BART miRNAs have no impact on
LCL growth or survival in vitro[26], or that the entire BART
region can be deleted without impacting the transforming capacity
of the virus[35] or that the prototypical laboratory strain B95-8
has most of the BART region, including most of Cluster 2, deleted
yet is unimpaired in its transforming ability. The explanation for
this discrepancy may lie in the fact that Marquitz et al performed
their studies in an epithelial cell line not in B cells. Taken together
these results suggest that the Latency III associated miRNAs we
have identified, may play a crucial survival role in vivo for newly
infected naı¨ve B lymphoblasts activated by the EBV Latency III
program but that this role is dispensable for in vitro growth much
as has been shown for LMP2 [36,37]. We assume that the specific
up regulation of this group of miRNAs in tumors implies they
could play a similar survival role in tumor development.
Our results suggest that expression of the Latency III associated
BARTS is coordinately regulated. It seems unlikely that this is
occurring at the level of transcription/splicing. It is known that the
BART miRNAs are derived from the first four introns of the
BART transcript prior to the splicing event [42] and the miRNAs
absent from GCB and MemB cells are not contiguous but
randomly distributed among these introns. For examples, Bart 15
is located in the region between exon 1a and 1b whereas Bart 10
and Bart 20 are in the junction of exon 2 and 3. Therefore, it is
unlikely that the differential miRNA expression we have described
is related to the selection of splicing patterns. Other possible
Table 2. Copy number per cell of EBV miRNAs in normal
infected tissues and spontaneous lymphoblastoid cell lines.
miRNA1 LCL n=6 GCB n=5 MemB n=4
BHRF1-1 22 64 96 .
BHRF1-2 34 0 0 .
BHRF1-2* 494 0 0 .
BHRF1-3 8 0 0 .
2-5p 76 291 755
2-3p 1 0 0 .
1-5p 58 502 795
1-3p 167 399 617
3* 36 13 4
3 5 108 176
4 53 46 476
5 51 88 116
6-5p 9 63 49
6-3p 58 170 1046
15 327 0 0 .
17-5p 250 2 110
7 230 41 201
7* 8 0 0 .
8-5p 60 532 515
8-3p 116 598 1166
9* 0 0 0
10 38 0 0 .
10* 12 0 0 .
11-5p 16 164 316
11-3p 13 0 0 .
13 24 31 57
13* 5 0 0 .
14* 96 0 0 .
18-5p 42 279 294
18-3p 35 0 0 .
19-5p 11 80 255
20-5p 1 0 0 .
20-3p 0 0 0
22 23 203 358
1- The miRNAs are divided into transcriptional groups. Starting from the top
BHRF1, BART 2, BART Cluster 1, BART Cluster 2.
Arrows (.) denote miRNAs detected in LCL but not (,0.1 copies/cell) the GCB
or MemB cells.
doi:10.1371/journal.ppat.1002193.t002
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mechanisms that are known to regulate miRNA expression are
differential DNA methylation [43–45] and RNA editing both of
which have been shown to function on BART miRNAs [46,47].
However, these mechanisms defer rather than answer the question
as to why or how this particular subset of miRNAs is targeted for
coordinate expression. A mechanisms that we favor is based on the
observation that the stability of miRNAs is dependent on the
presence of their target mRNA [48]. In this case the absence of
miRNAs in GCB and MemB that are present in LCL and the
tumors would arise because the mRNAs targeted by those
miRNAs were only present in LCL and the cancers.
We were surprised to find that the four tumor types clustered
together in the heat map. This was irrespective of the tumor
type, tissue of origin or the EBV transcription program that they
employed. Perhaps more unexpected was our finding that
despite the very similar patterns of miRNA expression the
different tumor types were nevertheless clearly distinguished in
two separate assays (heat map/clustering and PCA) applied to
two completely separate data sets (p in both cases = 0.001). The
basis for this resolution is less clear since it is not associated with
any particular subset of miRNAs. Rather we discovered that a
majority of all subsets of five or more miRNAs and some subsets
as small as three were capable of distinguishing all four cancer
types. Even more curious was the finding that every miRNA is
capable of contributing to one of these subsets. Taken together,
these results mean that the signal distinguishing these cancers is
highly redundantly encoded across the miRNA expression
profiles. Such a distribution of information is uncommon indeed
may never have been reported before for a biological system.
However, this type of behavior is well known in physics and
computer science where there is a close analogy to secret
sharing algorithms [38,39]. For example, it is possible to share a
secret message among any number (in our case ,40) people in
such a way that if any 5 of them divulge their information to
each other, the message can be read. It is interesting to speculate
that the signal in our assays, i.e., the causes of or responses to
each cancer type is in some similar manner parceled out among
the miRNAs. How this might work at the molecular level is
unclear but we assume it must reflect extensive redundancy in
the miRNAs both in the number that target the same gene and
in targeting genes that lie in the same or parallel signaling
pathways related to tumor development. Evidence for such
layers of redundancy in miRNA function is well known [49–
52]and has recently been reported for both the Cluster 1 and 2
Figure 5. The profile of EBV BART miRNAs in LCL and neoplastic tissues. The average and standard deviation of miRNA expression after
normalization to the level of expression of the ubiquitous human small RNA RNU6b is shown. The stars indicate miRNAs that were consistently absent
from HD (blue) and LCL (grey) only. A. LCL versus the B cell tumors. Blue – Hodgkin’s disease; yellow – Burkitt’s lymphoma; grey LCL. B. LCL versus the
epithelial tumors. Green - gastric carcinoma; red - nasopharyngeal carcinoma; grey - LCL. This is the same data set for the tumor biopsies as shown in
Figure 3. N.B. The miRNAs are presented on the x-axis from left to right in the order that they appear in the viral genome (see Figure 1).
doi:10.1371/journal.ppat.1002193.g005
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Figure 6. The profile of EBV BHRF1 miRNAs in LCL and neoplastic tissues. The average and standard deviation of miRNA expression after
normalization to the level of expression of the ubiquitous human small RNA RNU6b is shown. The miRNAs were undetectable in GaCa. The numbers
above the bars indicate estimated copy number per cell based on values from the LCL.
doi:10.1371/journal.ppat.1002193.g006
Figure 7. Heat map of miRNA expression in all tissues tested. The data sets used in Figure 3 and 4 were normalized based on the fraction that
each miRNA comprised of the total EBV miRNA measured in each sample. A complete description is given in materials and methods. The relative up
and down regulation of miRNAs is indicated by red and green respectively. Dendrograms of clustering analysis for samples and miRNAs are displayed
on the top and left respectively. Tumors, forming a distinct branch on both the sample and miRNA dendrograms, are boxed in blue.
doi:10.1371/journal.ppat.1002193.g007
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BART miRNAs in reducing apoptosis susceptibility in an
epithelial cell line [41].
It has been suggested previously, based on cell lines, that the
copy number of BART miRNAs is higher in epithelial cells than B
cells. This is consistent with our estimates of the relative
abundance of the miRNAs in our tumor biopsy samples versus
the LCL. However, the correlation of high expression with
epithelial tissue is confounded by our measurement of relative
abundance in the MemB and GCB populations where the
expressed BART miRNAs are present at comparable levels to
the epithelial tumors. The exact meaning of these variable levels of
expression is therefore now unclear.
The only EBV latency transcription program that we found to
be associated with a specific pattern of miRNA expression was
Latency III characterized by up regulation of the Latency III
associated BART and BHRF1 miRNAs. The later serves as
validation for our approach since it has been reported [27] and
confirmed [15] previously. We found BHRF1 expression in some
of the tumor biopsies notably BL and HD although they were
present at a very low level which we estimate to be generally less
than one copy per cell. The absence of BHRF1 miRNAs from
EBV associated tumors is consistent with previous findings that
BHRF1 miRNAs were not found in biopsies from GaCa [53] and
DLBCL tissues [17]. By contrast we found abundant BHRF1
miRNAs in the tumor derived cell lines. This, together with our
finding that the BART miRNA expression profile in these lines
tended to resemble LCL more closely than the originating tumor
biopsies, casts doubt on the value of using such lines to study EBV
miRNAs.
In conclusion, we have presented the first comprehensive
profiling of EBV miRNAs from in vivo derived normal and
neoplastic tissue. These results demonstrate specific patterns of
expression in Latency III versus more restricted forms of latency
and deregulation of miRNA expression in tumors.
Materials and Methods
Cell lines and culture
The EBV-positive lymphoblastoid cell line (LCL) IB4 (gift of Dr.
Elliot Kieff) and the murine CB59 T cell line (gift of Dr. Miguel
Stadecker) were used respectively as the positive and negative
control for EBV. For miRNA profiling, six spontaneously EBV-
infected B LCLs (gift of Dr. Alan Rickinson) with different EBV
strains (type 1 or type 2), five EBV-positive Burkitt’s lymphoma
(BL) cell lines Rael (gift of Dr. Sam Speck), Jijoye, BL36, Raji and
Akata 2A8.1 (gift of Dr. Jeff Sample), the gastric carcinoma (GaCa)
line AGS/BX1 (gift of Dr Lindsey Hutt-Fletcher), the nasopha-
ryngeal carcinoma (NPC) line C666-1 and the Hodgkin’s disease
(HD)-derived cell line L591 (gift of Dr. Paul Murray) were
included in this study (Table 1). The EBV-negative BL lines Akata,
BJAB, DG75, BL2 and BL31, the NPC line HONE-1(gift of Dr.
Ronald Glaser), and the GaCa line AGS were used as the negative
controls. The GaCa cell lines were grown in Ham’s F-12 medium
containing 10% fetal bovine serum (FBS), 2 mM sodium pyruvate,
2 mM glutamine, and 100 IU of penicillin-streptomycin. All other
cell lines were maintained in RPMI 1640 medium with the same
supplements.
Ethics statement–clinical biopsies and primary cells
The research described herein was approved by the Tufts
University Institutional Review Board and our collaborating
institutions. Peripheral blood mononuclear cells (PBMCs) of whole
blood samples were provided by the University of Massachusetts at
Amherst Student Health Service as previously described. Adoles-
cents (ages 17 to 24 years) presenting to the clinic at the University
of Massachusetts at Amherst Student Health Service (Amherst)
with clinical symptoms consistent with AIM were recruited for this
study. Blood was collected following the obtainment of written
informed consent. These studies were approved by the Human
Studies Committee at the University of Massachusetts Medical
School (Worcester).
Table 3. miRNAs identified by heat map as up regulated in
normal infected tissue (GC and MemB) vs LCL vs tumor
biopsies and their counterparts identified by PCA.
Heat map1 PCA{
Up regulated
PC1 +
loading
PC2 +
loading
PC2 -
loading
LCL BHRF1-1 BHRF1-1
BHRF1-2 BHRF1-2
BHRF1-2* BHRF1-2*
BHRF1-3 BHRF1-3
2-3p 2-3p
7* 7*
10* 10*
15 15
17-5p 17-5p
18-3p 18-3p
Normal Tissue 1-3p
(MemB +GCB) 1-5p 1-5p
2-5p 2-5p
8-3p 8-3p
8-5p 8-5p
11-5p 11-5p
18-5p 18-5p
6-5p
Tumor
biopsies
3 3
3* 3*
5 5
6-3p 6-3p
6-5p 6-5p
7 7
9* 9*
10 10
11-3p 11-3p
13 13
13* 13*
14* 14*
19-5p 19-5p
20-3p 20-3p
20-5p 20-5p
22 22
7*
18-3p
1- See Figure 6.
{- See Figure 7 and Figure S2.
doi:10.1371/journal.ppat.1002193.t003
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Tonsils were collected from patients 18 years of age or younger
receiving routine tonsillectomies at the Tufts Medical Center at
Boston, MA. Informed consent was not obtained since this was
deidentified, discarded material and was deemed exempt by the
Tufts University Institutional Review Board.
Tumor biopsy samples for this study were obtained from the
archives of the Vrije Universiteit, Amsterdam (VU) medical
center. Consent was not obtained because we used left over
archival material from earlier studies (listed below). This was
approved by the Medical Ethical Committee of the VU University
Figure 8. Principal component analysis (PCA) of miRNA expression in all tissues tested. PCA was performed on the same data set as
shown in Figure 7. A. Second and third principal components B. First and second principal components. For a demonstration of all three components
simultaneously see Video S1.
doi:10.1371/journal.ppat.1002193.g008
Figure 9. Principal component analysis of miRNA expression in all tumors tested. PCA was performed on the same data set used in
Figure 3A. A. The first two principal components resolve the four tumor types. For a movie demonstrating the first three principal components see
Video S2. B. Subsets containing as few as 3 miRNAs resolve the tumor types. This figure plots the failure rate of different sized sets of miRNAs. For
each set size, 10,000 randomly chosen subsets were tested. N.B. this represents over sampling for the subset n= 3
doi:10.1371/journal.ppat.1002193.g009
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medical center, Amsterdam, The Netherlands according to the
code for proper secondary use of human tissue of the Dutch
Federation of Biomedical Scientific Societies (http://www.federa.
org). Burkitt’s lymphoma (BL) samples were collected in Malawi
from 1996–1998 under study nr. IC19-CT96-0132. Hodgkin’s
disease (HD) samples (all of nodular sclerosing subtype) were
collected in Amsterdam from 1994–2002 under studies nr. KWF-
VU1994-749 and 2001–2511 Gastric carcinoma (GaCa) samples
were collected in Amsterdam from 1999–2004 under study nr.
KWF1999–1990. Nasopharyngeal carcinoma (NPC) samples were
collected in Indonesia during 2001–2005 in studies KWF-IN2000-
02/03. A single case of HD was obtained from the Children’s
Hospital, Birmingham, UK, with permission from the Childhood
Cancer and Leukaemia Group (CCLG) of the United Kingdom.
This sample was used in accordance with Trent Research Ethics
Committee REC reference number 05/MRE04/. Written consent
was obtained and the sample taken under ethical approval
obtained from South Birmingham Research Ethics Committee.
EBV status of tumor biopsies was assessed based on EBER1/2
in situ hybridization using commercial PNA-based hybridization
probes (Dakocytomation, Glostrup, Denmark) and immunohisto-
chemical staining for EBNA1 and LMP1 using previously
described monoclonal antibodies[54,55].
Tonsils were cut into small fragments in phosphate-buffered
saline with 1% bovine serum albumin (PBSA) with razor blades.
Cells were obtained by filtering the fragment suspensions through
a 70 mm mesh size cell strainer. Mononuclear cells were isolated
from buffy coats using the standard Ficoll-Paque Plus (Fisher
Scientific) centrifugation method and saved for analysis.
Cell staining and flow cytometry
Germinal center B (GCB) and memory B (MemB) cell
populations were purified by fluorescence-activated cell sorting
(FACS). Surface staining for FACS analysis was performed by
standard procedures. Monoclonal antibodies against specific cell
surface markers including allophycocyanin (APC)-labeled anti-
CD19, phycoerythrin (PE)-anti-CD10, and fluorescein isothiocy-
anate (FITC)-anti-CD27 were used. GCB cells (CD19+CD10+)
and MemB cells (CD19+CD27+) were sorted from tonsil and
blood PBMCs, respectively as previously reported [5,56]. For
miRNA studies, 56106 to 107 GCB cells were sorted for RNA
isolation. Since the blood samples were small and MemB cells
(CD19+CD27+) only account for 0.5-2 % of PBMCs, we sorted all
the memory B cells into 106 CB59 cells prior to RNA isolation.
EBV miRNA profiling of CB59 cells indicated that it is
appropriate to use them as filler cells since they do not generate
detectable signals for any EBV miRNAs (data not shown).
Limiting dilution and DNA real-time PCR
Determination of the EBV frequency of infected cells in purified
GCB and MemB cells was done by limiting dilution and DNA
real-time PCR as described previously [12]. Briefly, FACS-gated
cells were sorted onto a 96-well plate with 10 replicates each of
serially diluted cells. Genomic DNA was isolated by Proteinase K
digestion, followed by real time Taqman DNA PCR specific for
the W-repeat genome of EBV. The fraction of EBV-negative wells
was calculated and the frequency of infected cells was estimated
using the Poisson distribution.
RNA extraction and multiplexed stem-loop RT-PCR
Total RNA was extracted from frozen sections or sorted cell
populations with Trizol (Invitrogen). The quantity and integrity of
the RNA was assessed by nanodrop and by the Agilent
Bioanalyzer. EBV miRNA expression was assessed by real-time
multiplex reverse transcript (RT)-PCR as previously detailed [16].
Briefly, multiple stem-loop RT primers specific for the 39 end of
each mature miRNA were mixed and applied to RT reaction,
followed by Taqman PCR using primers and probes specifically
assigned to each miRNA. Synthetic oligonucleotides representing
all of the miRNAs were employed to generate the standard curves.
The small cellular nuclear RNA U6 was used as the internal
control for normalization. EBV-negative materials were used for
negative controls. Profiles were performed in duplicate and
repeated three times. Since, in our to-be-profiled sample pool
the frequency of infected cells in 56106 to 107 GCB ranged
Table 4. Copy number per cell of EBV BHRF1 miRNAs in cell lines.
Cell Line LCL Jijoye BL36 Rael Raji Akata 2A8.1 L591 AGS-BX1 C666-1
Origin BL BL BL BL BL HD GaCa NPC
BHRF1-1 22 2 126 0 227 74 114 5 0
BHRF1-2 34 88 190 154 644 210 248 27 0
BHRF1-2* 494 717 401 212 115 407 558 582 12
BHRF1-3 8 35 140 45 1 68 56 12 0
doi:10.1371/journal.ppat.1002193.t004
Figure 10. Unlike BL biopsies, the miRNA expression profile for
BL derived cell lines is indistinguishable from LCL by principal
component analysis. For a movie of this analysis see Video S3. Yellow
– BL derived cell lines (n = 5); green; GaCa derived cell line; blue – HD
derived cell line; red; NPC derived cell line; grey LCL (n = 6).
doi:10.1371/journal.ppat.1002193.g010
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between 6–130 per 105 GCB, most of the RNA was derived from
cellular rather than viral origin. To test if this compromised any of
the PCR assays we profiled 56106 and 107 EBV negative cells. Of
the 38 miRNAs tested only four (BARTs 9, 12, 16and 19-3p) gave
detectable and significant signals with EBV negative cells so these
were excluded from further analysis involving these cell types.
Analytical methods
The data we have addressed here consist of copy numbers for
34 EBV miRNAs (38 for the cell lines and biopsies) from each of 43
samples. These include biopsies from four tumor types, EBV+
MemB-cells and GCB-cells from normal carriers, lymphoblastoid cell
lines and tumor derived cell lines. We can consider these as a
collection of 43 points in 34-dimensional space, i.e., x1, . . . ,x43[R
34.
In order to perform specific comparisons, we have analyzed subsets of
these points, which we will refer to generically as x1, . . . ,xn[R
34. We
normalized each sample to the total EBV miRNA count of that
sample. That is, given a sample xi~(xi 1, . . . ,xi 34)
we normalized this to:
yi~
1
X34
j~1
xi j
0
BBBB@
1
CCCCA(xi1, . . . ,xi34)
We normalized each component of the yi vectors by taking the Z-
score for that component across all samples. That is, we took
zi~(zi 1, . . . ,zi 34) where zi j is the Z-score of yi j among the values
yi j , . . . ,yn j .
Heat Maps We performed heat maps on z1,:::,zn using
MATLAB’s clustergram function. This produces a rectangular
array of squares whose rows correspond to miRNAs and whose
columns correspond to samples. The color of the square denotes the
relative up- or down-regulation of the miRNA in that sample. In
addition, it produces dendrograms for the rows and columns which
are computed using hierarchical clustering. The ordering of the rows
and columns is the one most compatible with the dendrograms.
PCA. We performed PCA on z1,:::,zn using MATLAB’s pca
function. We then produced 3-dimensional plots (convex hulls) by
using the first 3 principal components.
Resolution and convex hulls. We are able to detect if the convex
bodies are resolved or disjoint by the following computation.
Given a set of points p1,:::,pm, their convex hull is the set of
points of the form
Xm
i~1
aipi
where for each i, ai $0 and
Xm
i~1
ai~1
Put differently the convex hull of a set of points is the set of all
possible weighted averages of these points.
Given two sets of points, p1,:::,pm and q1,:::,qn, we can
determine whether their convex hulls are disjoint by attempting
to minimize the distance between
Xm
i~1
aipi and
Xn
i~1
biqi
subject to the appropriate constraints. The minimum value is 0 if
and only if the two convex hulls meet. We performed this
constrained minimization using MATLAB’s fmincon function .
The solid bodies shown in Figures 8–10 are the convex hulls of
the data points grouped according to cell type. In Figure 9A they
resolve the four cancer types, that is to say, these four convex hulls
are disjoint. We performed two in silico experiments to establish a
p-value for this result. Both of these involve examining large
numbers of cases and determining whether the resulting convex
hulls are disjoint. In the first in silico experiment we considered the
null hypothesis that the points are randomly located in the cube.
We generated sets of 20 random points in the unit 3-dimensional
cube. We grouped these points into groups of 6, 6, 3 and 5 (similar
to our cancer types) and determined whether the resulting convex
hulls are disjoint. Note that the probability of these convex hulls
being disjoint is independent of the size of the cube. Out of 10,000
trials, 12 were disjoint giving an estimated p-value of ,0.001.
In the second in silico experiment we tested the null hypothesis
that it is some hidden feature of the points themselves and not their
grouping into the four cancer types that is responsible for the
separation of the convex hulls. To test this we used MATLAB’s
randperm function to randomly assign the points of Figure 9A to
groups of 6, 6, 3 and 5 and tested whether the resulting convex
hulls were disjoint. Out of 10,000 trials, 7 were disjoint giving an
estimated p-value of ,0.001.
Digital knock-out, redundancy and the search for
relevant miRNAs. To discover which miRNAs might have
the most biological relevance we reasoned that these must be the
ones responsible for the orderliness of Figure 9A. This led us to
systematically study which subsets succeed in resolving the cancers.
For a range of subset sizes s=3 to s=20, we generated 10,000
random subsets of size s drawn from the 38 EBV miRNAs
appearing in our samples. (miRNA BHRF1–2* was not detected
in any of the samples and was omitted from this subset analysis).
Note that we have over-sampled subsets of size s=3 since
38
3
 
~8436. For each subset, we set to zero the data for all
miRNAs not appearing in the subset and performed PCA as
described above to observe if the convex hulls remained disjoint or
collided. Note that occasionally MATLAB was unable to complete
the PCA computation, for example, when inverting an ill-
conditioned matrix leads to numerical overflow. (This occurred
in less than 1% of trials, predominantly in sets of size 3). We
recorded each subset and the result of the computation. We then
queried this database of subsets in several ways attempting to
determine which miRNAs play the largest role in resolving the
cancer types.
Test 1: number of occurrences of each miRNA in subsets
that resolve. We counted the number of times each miRNA
appears across all trials in those subsets that successfully resolved
the four cancer types. The result for each miRNA is derived from
an arbitrary choice of 10,000 total trials of each size.
Test 2: number of times the addition of each miRNA
converts a failing subset into a successful subset. We
searched through our database of failing and succeeding subsets to
discover cases in which the addition of a single miRNA converts a
failing subset into a successful one.
Supporting Information
Figure S1 Heat map of tissue samples from Figure 6 plus cell lines
from all four tumor types.Cell lines are indicated by colored dots:
yellow - BL lines; red - NPC line; blue – HD line; green- GaCa line.
(TIF)
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Figure S2 Positive and negative loading (contributions) of the
miRNAs to the 1st and 2nd principal components of the PCA
shown in Figure 8.
(TIF)
Video S1 PCA from Figure 7 showing all three principal components.
(AVI)
Video S2 PCA from Figure 8 showing all three principal
components.
(AVI)
Video S3 PCA from Figure 9 showing all three principal
components.
(AVI)
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